Gennex Laboratories Limited

BSE:531739 Stock Report

Market Cap: ₹3.7b

Gennex Laboratories Past Earnings Performance

Past criteria checks 4/6

Gennex Laboratories has been growing earnings at an average annual rate of 42.9%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 10.5% per year. Gennex Laboratories's return on equity is 9.3%, and it has net margins of 15.4%.

Key information

42.9%

Earnings growth rate

31.2%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate10.5%
Return on equity9.3%
Net Margin15.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Gennex Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:531739 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,125173730
30 Jun 24985150760
31 Mar 24867132790
31 Dec 23719107900
30 Sep 2366690910
30 Jun 2368270850
31 Mar 2365649810
31 Dec 2267140820
30 Sep 2269737760
30 Jun 2264837720
31 Mar 2261239730
31 Dec 2157644720
30 Sep 2156449770
30 Jun 2157546730
31 Mar 2159640740
31 Dec 2055228700
30 Sep 2054517700
30 Jun 2053014700
31 Mar 2056219710
31 Dec 1965320730
30 Sep 1965827700
30 Jun 1963425650
31 Mar 1956322630
31 Dec 1849816640
30 Sep 1846410590
30 Jun 1846010580
31 Mar 184438570
31 Dec 174298540
30 Sep 1741015540
30 Jun 1742125530
31 Mar 1741927510
31 Dec 1640832470
30 Sep 1639331460
30 Jun 1637025420
31 Mar 1638623430
31 Dec 1537921610
30 Sep 1535412590
30 Jun 153358660
31 Mar 153197350
31 Dec 143261620
30 Sep 143617610
30 Jun 143595320
31 Mar 143502590
31 Dec 1333410450

Quality Earnings: 531739 has a high level of non-cash earnings.

Growing Profit Margin: 531739's current net profit margins (15.4%) are higher than last year (13.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 531739's earnings have grown significantly by 42.9% per year over the past 5 years.

Accelerating Growth: 531739's earnings growth over the past year (91.3%) exceeds its 5-year average (42.9% per year).

Earnings vs Industry: 531739 earnings growth over the past year (91.3%) exceeded the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: 531739's Return on Equity (9.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 23:22
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gennex Laboratories Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution